Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers

Abstract

The purpose of this study was to compare the pharmacokinetics and bioavailability of two commercial brands of delayed release divalproex sodium (CAS 76584-70-8) tablets in healthy male Iranian volunteers in fasted state. Each single-dose, randomized, open-label, blind study was conducted according to a crossover design in subjects. A washout interval of 14 days separated the doses in each study. Serial venous blood samples were obtained over 24 h after each administration to measure drug in serum, and placed into tubes containing sodium heparin. Then the separated plasma was kept frozen at −20 °C for subsequent analysis. The plasma concentrations of drug were analyzed by a validated sensitive HPLC method with UV detection. Mean maximum serum concentrations of 124.5 ± 34.8 μg/ml and 134.2 ± 31.1 μg/ml were obtained for the test and reference products, respectively. The and were 2023.8 ± 578.8 1 μg h/ml and 2705.3 ± 792.1 μg h/ml for the test and 2068.2 ± 526.4 μg h/ml and 2729.6 ± 698.2 μg h/ml for the reference formulation, respectively. The calculated 90% confidence intervals for the ratio of C_max (87.2-101.5%), (92.1-108.6%) and (93.1 – 110.6%) values for the test and reference products were all within the 85-120% interval proposed by the FDA and EMA. Therefore the divalproex sodium tablets of the test and reference products are bioequivalent in terms of rate and extent of absorption.

Key words

Bioavailability - Delayed release tablets - Divalproex sodium - Fasted state

• References

• 1 Dutta S, Zhang Y, Selness DS, Lee LL, Williams LA, Sommerville KW. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res. 2002; 49 (1) 1-10
• 2 Dutta S, Zhang Y, Lee LL, O’Dea R. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers. Biopharm Drug Dispos. 2004; 25 (8) 3537
• 3 Manivannan R, Balasubrmaniam A, Partiban K, Gandhil R, Senthilkumar B, Senthilkumar N. Formulation development and evaluation of Divsodium extended release tablet. Int J Pharm Pharm Sci. 2010; 2 (3) 83-5
• 4 Fagiolino P, Martin O, Gonzaz N, Malanga A. Actual bioavailability of divalproex sodium extended-release tablets and its clinical implications. J Epilepsy Clin Neurophysiol. 2007; 13 (2) 75-8
• 5 Smith MC, Centorrino F, Welge JA, Collins MA. Clinical comparison of extended-release divalproex versus delayed-release divalproex: Pooled data analyses from nine trials. Epilepsy Behavior. 2004; 5 (5) 746-51
• 6 Keck Jr PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002; 63 (4) 3-11
• 7 Centorrino F, Kelleher JP, Berry JM, Salvatore P, Eakin M, Fogarty KV et al Pilot comparison of extended-release and standard preparations of divalproex sodium in patients with bipolar and schizoaffective disorders. Am J Psychiatry. 2003; 160 (7) 1348-50
• 8 Fujii A, Yasui-Furukori N, Nakagami T, Niioka T, Saito M, Sato Y et al Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations. Drug Design Develop Ther. 2008; (2) 139-44
• 9 Thibault M, Blume WT, Saint-Hilaire JM, Zakhari R, Sommerville KW. Divalproex extended-release versus the original divalproex tablet: Results of a randomized, crossover study of well-controlled epileptic patients with primary generalized seizures. Epilepsy Res. 2002; 50 (3) 243-9
• 10 Islambulchilar Z, Valizadeh H, Zakeri-Milani P. Rapid HPLC determination of pioglitazone in human plasma by protein precipitation and its application to pharmacokinetic studies. J AOAC Int. 2010; 93 (3) 876-81
• 11 Valizadeh H, Nemati M, Hallaj-Nezhadi S, Ansarin M, Zakeri-Milani P. Single dose bioequivalence study of alpha-methyldopa tablet formulations using a modified HPLC method. Arzneimittelforschung. 2010; 60 (10) 607-11
• 12 Dutta S, Zhang Y, Conway JM, Sallee FR, Biton V, Reed MD et al Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol. 2004; 30 (5) 330-7
• 13 Dutta S, Reed RC, Cavanaugh JH. Pharmacokinetics and safety of extended-release divalproex sodium tablets: Morning versus evening administration. Am J Health Syst Pharm. 2004; 61 (21) 2280-3
• 14 Cloyd JC, Kriel RL, Jones-Saete CM, Ong BY, Jancik JT, Remmel RP. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr. 1992; 120 (4 I) 634-8
• 15 Rha JH, Jang IJ, Lee KH, Chong WS, Shin SG, Lee N et al Pharmacokinetic comparison of two valproic acid formulations-a plain and a controlled release enteric-coated tablets. J Korean Med Sci. 1993; 8 (4) 251-6
• 16 Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, Azarmi Y, Valizadeh H. Simultaneous determination of naproxen, ke-toprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal. 2005; 39 (3–4) 624-30
• 17 Valizadeh H, Zakeri-Milani P, Islambulchilar Z, Tajerzadeh H. A simple and rapid high-performance liquid chromatography method for determining furosemide, hydrochlorothiazide, and phenol red: applicability to intestinal permeability studies. J AOAC Int. 2006; 89 (1) 88-93
• 18 Zakeri-Milani P, Valizadeh H, Islambulchilar Z, Damani S, Mehtari M. Investigation of the intestinal permeability of Ciclosporin using the in situ technique in rats and the relevance of P-glycoprotein. Arzneimittelforschung. 2008; 58 (4) 188-92
• 19 Dutta S, Reed RC. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States. Epilepsy Res. 2007; 73 (3) 275-83
• 20 Zakeri-Milani P, Valizadeh H, Ghanbarzadeh S, Nemati M. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. Arzneimittelforschung. 2009; 59 (8) 429-32
• 21 Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two Cefixime formulations administered orally in healthy male volunteers. Arzneimittelforschung. 2008; 58 (2) 97-100
• 22 Valizadeh H, Barghi L, Jalilian H, Islambulchilar Z, Zakeri-Milani P. Bioequivalence of fexofenadine tablet formulations assessed in healthy iranian volunteers. Arzneimittelforschung. 2009; 59 (7) 345-9
• 23 FDA. Guidance for industry, bioavailability and bioequivalence studies for orally administered drug products; General considerations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), USA http://www.fda.gov/cder/guidance/5356fnl.pdf 2003
• 24 EMA. Guideline on the Investigation of Bioequivalence. European Medicines Agency, Pre-Authorisation Evaluation of Medicines for Human Use, Committee for Medicinal Products for Human Use (CHMP), London, UK http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf